United States · FDA National Drug Code directory
Xiidra
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 0078-0911_3cabbaea-c2bf-971c-e063-6394a90a4931
- Product NDC
- 0078-0911
- Form
- SOLUTION/ DROPS
- Composition / generic term
- Lifitegrast
- Labeler
- Novartis Pharmaceuticals Corporation
- Marketing category
- NDA
- Marketing start / end (source format)
- 20160711
- Source listing expiry
- 20261231
Source-listed ingredients
- LIFITEGRAST — 50 mg/mL
These values do not establish equivalence or a dose recommendation.
Packages
- 12 POUCH in 1 CARTON (0078-0911-12) / 5 AMPULE in 1 POUCH (0078-0911-05) / .2 mL in 1 AMPULE · 0078-0911-12
- 4 POUCH in 1 CARTON (0078-0911-94) / 5 AMPULE in 1 POUCH (0078-0911-95) / .2 mL in 1 AMPULE · 0078-0911-94
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →